Search results
Showing 2901 to 2950 of 4086 results for patient
Awaiting development Reference number: GID-TA11150 Expected publication date: TBC
Awaiting development Reference number: GID-TA11756 Expected publication date: TBC
Awaiting development Reference number: GID-TA11668 Expected publication date: TBC
Awaiting development Reference number: GID-TA11226 Expected publication date: TBC
Awaiting development Reference number: GID-TA11227 Expected publication date: TBC
Awaiting development Reference number: GID-TA11841 Expected publication date: TBC
Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]
Awaiting development Reference number: GID-TA11123 Expected publication date: TBC
Awaiting development Reference number: GID-TA11532 Expected publication date: TBC
Awaiting development Reference number: GID-TA11591 Expected publication date: TBC
Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC
Awaiting development Reference number: GID-TA11838 Expected publication date: TBC
Awaiting development Reference number: GID-TA11358 Expected publication date: TBC
Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]
Awaiting development Reference number: GID-TA11354 Expected publication date: TBC
Awaiting development Reference number: GID-TA11335 Expected publication date: TBC
Awaiting development Reference number: GID-TA11717 Expected publication date: TBC
Awaiting development Reference number: GID-TA11783 Expected publication date: TBC
Awaiting development Reference number: GID-TA11194 Expected publication date: TBC
Awaiting development Reference number: GID-TA11137 Expected publication date: TBC
Awaiting development Reference number: GID-TA11110 Expected publication date: TBC
Awaiting development Reference number: GID-TA11049 Expected publication date: TBC
Awaiting development Reference number: GID-TA11860 Expected publication date: TBC
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]
Awaiting development Reference number: GID-TA11892 Expected publication date: TBC
Awaiting development Reference number: GID-TA11871 Expected publication date: TBC
Awaiting development Reference number: GID-TA11698 Expected publication date: TBC
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]
Awaiting development Reference number: GID-TA11283 Expected publication date: TBC
Awaiting development Reference number: GID-TA11858 Expected publication date: TBC
Awaiting development Reference number: GID-TA11517 Expected publication date: TBC
Awaiting development Reference number: GID-TA11827 Expected publication date: TBC
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Awaiting development Reference number: GID-TA11111 Expected publication date: TBC
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]
Awaiting development Reference number: GID-TA11821 Expected publication date: TBC
Awaiting development Reference number: GID-TA11816 Expected publication date: TBC
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]
Awaiting development Reference number: GID-TA11393 Expected publication date: TBC
CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]
Awaiting development Reference number: GID-TA11182 Expected publication date: TBC
Awaiting development Reference number: GID-TA11839 Expected publication date: TBC
Awaiting development Reference number: GID-TA11778 Expected publication date: TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]
Awaiting development Reference number: GID-TA11076 Expected publication date: TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]
Awaiting development Reference number: GID-TA11053 Expected publication date: TBC
Awaiting development Reference number: GID-TA11219 Expected publication date: TBC
Awaiting development Reference number: GID-TA11048 Expected publication date: TBC
Awaiting development Reference number: GID-TA11200 Expected publication date: TBC
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]
Awaiting development Reference number: GID-TA11073 Expected publication date: TBC
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]
Awaiting development Reference number: GID-TA11814 Expected publication date: TBC
Awaiting development Reference number: GID-TA11671 Expected publication date: TBC
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]
Awaiting development Reference number: GID-TA11746 Expected publication date: TBC
In development Reference number: GID-TA11372 Expected publication date: TBC
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
Autism spectrum disorder in under 19s: support and management (CG170)
This guideline covers children and young people with autism spectrum disorder (across the full range of intellectual ability) from birth until their 19th birthday. It covers the different ways that health and social care professionals can provide support, treatment and help for children and young people with autism, and their families and carers, from the early years through to their transition into young adult life.
Cancer: invasive cancer diagnosed via emergency routes (IND1)
This indicator covers the proportion of invasive cases of cancer diagnosed via an emergency route. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCC01